Abstract
Acute myeloid leukemia (AML) is defined as ≥20% myeloblasts, representing a change from original guidelines where ≤30% blasts were considered as myelodysplastic syndromes (MDS), and 20-29% blasts classified as refractory anemia with excess blasts in transformation (RAEB-T). Whether the diagnostic bone marrow blast percentage has current value with regards to patient prognostication or identification of optimal treatment strategies is unclear. We retrospectively studied 1652 treatment-naïve adults with MDS or AML and ≥10% blasts from January 2000 to April 2014. Patients with 20-29% blasts were more similar to MDS patients in terms of advanced age, increased frequency of poor-risk cytogenetics, lower WBC count, and less frequent NPM1 and FLT3-ITD mutations. Median overall survival of MDS and RAEB-T were similar, 16.0 and 16.0 months, compared to 13.5 months for AML with ≥30% blasts (P = 0.045). Multivariate analysis showed inferior survival with increased age (HR 1.81 age 60-69, HR 2.68 age ≥70, P < 0.0005); poor-risk cytogenetics (HR 2.25, P < 0.0005); therapy-related disease (HR 1.44, P < 0.0005); and markers of proliferative disease including WBC ≥25 × 10(9) /L (HR 1.35, P = 0.0003), elevated LDH count (HR 1.24, P = 0.0015), a...Continue Reading
References
Aug 1, 1976·British Journal of Haematology·J M BennettC Sultan
Sep 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S H BernsteinC D Bloomfield
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Apr 3, 2004·European Journal of Haematology·Anna AnderssonThoas Fioretos
Jan 26, 2006·Cancer·Hagop KantarjianElihu Estey
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Apr 13, 2006·Blood·Bruce D ChesonHagop Kantarjian
Jul 15, 2006·Blood·Stefan FröhlingUNKNOWN German-Austrian AML Study Group
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Jul 12, 2008·Cancer·Hagop KantarjianGuillermo Garcia-Manero
Nov 21, 2008·Blood·Asa Rangert DerolfMagnus Björkholm
Nov 3, 2009·Blood·Hartmut DöhnerUNKNOWN European LeukemiaNet
May 6, 2010·Blood·Christoph RölligUNKNOWN Study Alliance Leukemia
Jul 27, 2010·Blood·Susan P WhitmanClara D Bloomfield
Dec 22, 2011·Blood·Frank G RückerHartmut Döhner
Jun 29, 2012·Blood·Peter L GreenbergDetlef Haase
Sep 28, 2012·Current Opinion in Oncology·Gail J Roboz
May 2, 2013·Cancer·Mya S TheinMaria R Baer
Dec 10, 2014·Nature·Terrence N WongRichard K Wilson
Citations
Dec 15, 2017·Veterinary and Comparative Oncology·L L DavisT Stokol
Oct 27, 2017·Expert Review of Hematology·Roberto CastelliGiorgio Lambertenghi-Deliliers
Apr 6, 2018·Blood·Abby StatlerMikkael A Sekeres
Jan 24, 2019·Blood·Tiffany N Tanaka, Rafael Bejar
Apr 13, 2019·American Journal of Hematology·Paolo StratiFarhad Ravandi
Dec 13, 2019·British Journal of Haematology·Shilpa PaulElias J Jabbour
Nov 27, 2019·Journal of Clinical Pharmacology·Swan LinAna Ruiz-Garcia
Jan 25, 2020·Annals of Hematology·Omar AlkharabshehAref Al-Kali
Aug 8, 2020·PloS One·Kwai Han YooSeong Kyu Park
Oct 12, 2018·Leukemia & Lymphoma·Chen MeiHongyan Tong
Jul 24, 2020·International Journal of Molecular Sciences·Edit KotogányGábor J Szebeni
Mar 20, 2021·Annals of Hematology·Michael HeuserJorge E Cortes
Oct 1, 2020·Journal of Clinical Medicine·Inke De HaesSébastien Anguille
Sep 1, 2021·Journal of Cancer Research and Clinical Oncology·Elizabeth HubscherPaul D'Amico
Oct 7, 2021·Cancer·Hagop M KantarjianElias J Jabbour